SLS Stock In Focus As Alliance Global Sees 92% Upside Following AML Trial Updates

• Both SLS009 and Galinpepimut-S are designed to address different stages of acute myeloid leukemia.
• Alliance Global said the updates on SLS009 and GPS strengthen the investment thesis for the company’s pipeline.
• SLS009 is being tested in early-stage acute myeloid leukemia, showing promising effectiveness and tolerability in patients.

Alliance Global has increased its price target for Sellas Life Sciences (SLS) shares to $10 from $7.50, maintaining a ‘Buy’ rating after the biotech firm shared progress updates on its clinical-stage treatments.

The new price target implies a potential 92% upside to the stock’s closing price on Thursday. The firm’s optimism comes as Sellas Life Sciences detailed developments for its two leading candidates, SLS009 and Galinpepimut-S.

Clinical Advancements Highlight Potential

Both SLS009 and Galinpepimut-S are designed to address different stages of acute myeloid leukemia (AML) in patients. Alliance Global said that these updates strengthen the investment thesis for the company’s pipeline, offering potential upside for shareholders, according to TheFly. 

LS009 is currently in clinical testing for patients in the initial phases of acute myeloid leukemia, with the company reporting encouraging signs of efficacy and tolerability. The therapy is being closely watched as a potential new treatment avenue for patients with limited options.

On Tuesday, Sellas announced that preclinical data for its CDK9 inhibitor, SLS009 (tambiciclib), will be presented in a poster session at the American Association for Cancer Research (AACR) conference, April 17–22 in San Diego.

Sellas Life Sciences' stock traded over 5% higher on Friday morning. Retail sentiment on Stockwtits around the stock remained in ‘bearish’ territory amid ‘low’ message volume levels. 

Galinpepimut-S Focuses On Advanced Patients

Galinpepimut-S is aimed at individuals with more progressed disease. Early trial results suggest it could complement existing therapies, providing a targeted immunotherapy approach. 

“We are advancing toward the final analysis of our Phase 3 REGAL trial evaluating GPS in AML patients who have achieved complete remission following second-line salvage therapy.”

— Angelos Stergiou, President And CEO, Sellas Life Sciences

The trial will conduct its final analysis after 80 survival events; as of Dec. 26, 2025, 72 events occurred, with the study still blinded, pending database lock, analysis, and topline results release.

SLS stock has gained over 43% year-to-date. 

Also See: SMCX ETF Plummets 55% As Super Micro Legal Troubles And Export Violations Weigh On Investor Sentiment

For updates and corrections, email newsroom[at]stocktwits[dot]com.